CIBC Asset Management Inc Invests $221,000 in Alnylam Pharmaceuticals, Inc. (ALNY)
CIBC Asset Management Inc acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,777 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. First Manhattan Co. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $135,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $148,000. Westpac Banking Corp purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $202,000. Prudential Financial Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at $215,000. Finally, Capstone Asset Management Co. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $232,000. Institutional investors own 88.99% of the company’s stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 81.42 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The firm’s market capitalization is $7.47 billion. The stock has a 50 day moving average of $80.83 and a 200 day moving average of $63.46.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.12. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.05) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.21) earnings per share for the current fiscal year.
Several research analysts have recently weighed in on ALNY shares. Piper Jaffray Companies set a $116.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 17th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a report on Monday, May 15th. Chardan Capital reduced their target price on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a report on Monday, May 15th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $102.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $81.74.
In other news, major shareholder Sanofi acquired 297,501 shares of the business’s stock in a transaction dated Wednesday, May 31st. The stock was bought at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laurie Keating acquired 11,500 shares of the business’s stock in a transaction dated Tuesday, May 30th. The stock was purchased at an average price of $65.35 per share, with a total value of $751,525.00. Following the completion of the transaction, the senior vice president now directly owns 11,500 shares of the company’s stock, valued at approximately $751,525. The disclosure for this purchase can be found here. 4.30% of the stock is owned by company insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.